NEW YORK (GenomeWeb) – Myriad RBM said this week that it has signed a deal with Sanofi to measure cardiovascular risk biomarkers in subjects participating in the pharma firm's Phase III trial for its type II diabetes drug lixisenatide.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.